FDA approves Lupin's Tavaborole Topical Solution
09 February 2021 | News
Tavaborole Topical Solution, 5 per cent, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.
Source credit: Shutterstock
Global pharma major Lupin Limited announced that it has received approval for its Tavaborole Topical Solution, 5 per cent, from the United States Food and Drug Administration, to market a generic equivalent of Kerydin® Topical Solution, 5 per cent, of Anacor Pharmaceuticals, Inc. The product will be manufactured at Lupin’s facility in Pithampur, India.
Tavaborole Topical Solution, 5 per cent, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. Tavaborole Topical Solution had estimated annual sales of $76 million in the US (IQVIA MAT December 2020).
